Glioblastoma multiforme (GBM) and the mesenchymal GBM subtype in particular are highly malignant tumors that frequently exhibit regions of severe hypoxia and necrosis. Because these features correlate with poor prognosis, we investigated microRNAs whose expression might regulate hypoxic GBM cell survival and growth. We determined that the expression of microRNA-218 (miR-218) is decreased significantly in highly necrotic mesenchymal GBM, and orthotopic tumor studies revealed that reduced miR-218 levels confer GBM resistance to chemotherapy. Importantly, miR-218 targets multiple components of receptor tyrosine kinase (RTK) signaling pathways, and miR-218 repression increases the abundance and activity of multiple RTK effectors. This elevated RTK signaling also promotes the activation of hypoxia-inducible factor (HIF), most notably HIF2α. We further show that RTK-mediated HIF2α regulation is JNK dependent, via jun proto-oncogene. Collectively, our results identify an miR-218-RTK-HIF2α signaling axis that promotes GBM cell survival and tumor angiogenesis, particularly in necrotic mesenchymal tumors. N aturally occurring oxygen (O 2 ) gradients serve as morphogenic signals in rapidly growing embryonic tissues (1) but become extreme in pathophysiological conditions such as ischemia or solid tumors. Chronic exposure to severe O 2 deprivation frequently produces necrotic zones surrounded by densely packed, hypoxic tumor cells. This cellular architecture is a common feature of glioblastoma multiforme (GBM), highly malignant brain tumors with a median patient survival of only 12-14 mo (2). Pseudopalisading GBM cells at the periphery of necrotic areas exhibit nuclear hypoxia-inducible factor 1α (HIF1α) protein accumulation and express hypoxia-regulated genes that control angiogenesis, extracellular matrix degradation, and invasive behavior (3, 4). Recent genomic sequencing and transcriptome analyses stratified GBM into distinct subtypes, including mesenchymal and proneural (5, 6). Importantly, patients with the aggressive mesenchymal subtype exhibit a particularly high degree of tumor necrosis (6). Moreover, an independent study revealed that GBM samples with high levels of necrosis are significantly enriched for the mesenchymal transcriptional gene signature (4). In particular, hypoxic GBM cells surrounding necrotic zones express high levels of the mesenchymal transcription factors C/EBP-β and C/EBP-δ, indicating a clear association between hypoxia, necrosis, and a mesenchymal GBM cellular identity (4).
Glioblastoma multiforme (GBM) and the mesenchymal GBM subtype in particular are highly malignant tumors that frequently exhibit regions of severe hypoxia and necrosis. Because these features correlate with poor prognosis, we investigated microRNAs whose expression might regulate hypoxic GBM cell survival and growth. We determined that the expression of microRNA-218 (miR-218) is decreased significantly in highly necrotic mesenchymal GBM, and orthotopic tumor studies revealed that reduced miR-218 levels confer GBM resistance to chemotherapy. Importantly, miR-218 targets multiple components of receptor tyrosine kinase (RTK) signaling pathways, and miR-218 repression increases the abundance and activity of multiple RTK effectors. This elevated RTK signaling also promotes the activation of hypoxia-inducible factor (HIF), most notably HIF2α. We further show that RTK-mediated HIF2α regulation is JNK dependent, via jun proto-oncogene. Collectively, our results identify an miR-218-RTK-HIF2α signaling axis that promotes GBM cell survival and tumor angiogenesis, particularly in necrotic mesenchymal tumors. N aturally occurring oxygen (O 2 ) gradients serve as morphogenic signals in rapidly growing embryonic tissues (1) but become extreme in pathophysiological conditions such as ischemia or solid tumors. Chronic exposure to severe O 2 deprivation frequently produces necrotic zones surrounded by densely packed, hypoxic tumor cells. This cellular architecture is a common feature of glioblastoma multiforme (GBM), highly malignant brain tumors with a median patient survival of only 12-14 mo (2) . Pseudopalisading GBM cells at the periphery of necrotic areas exhibit nuclear hypoxia-inducible factor 1α (HIF1α) protein accumulation and express hypoxia-regulated genes that control angiogenesis, extracellular matrix degradation, and invasive behavior (3, 4) . Recent genomic sequencing and transcriptome analyses stratified GBM into distinct subtypes, including mesenchymal and proneural (5, 6) . Importantly, patients with the aggressive mesenchymal subtype exhibit a particularly high degree of tumor necrosis (6) . Moreover, an independent study revealed that GBM samples with high levels of necrosis are significantly enriched for the mesenchymal transcriptional gene signature (4) . In particular, hypoxic GBM cells surrounding necrotic zones express high levels of the mesenchymal transcription factors C/EBP-β and C/EBP-δ, indicating a clear association between hypoxia, necrosis, and a mesenchymal GBM cellular identity (4) .
Elucidating the biological mechanisms whereby hypoxic tumor cells acquire the ability to survive and migrate under severe conditions is of significant clinical importance. Because microRNAs (miRNAs) are known to regulate complex cellular processes, including proliferation, differentiation, motility, and survival (7, 8) , we investigated how specific miRNAs control growth within the GBM tumor microenvironment. Although microRNA-218 (miR-218) previously was shown to be repressed in GBM relative to normal brain tissue (9, 10), we determined that miR-218 is reduced further in highly necrotic and hypoxic GBM, as compared with less necrotic samples. To delineate the role of miR-218 repression in GBM further, we performed intracranial xenograft assays and determined that miR-218 silencing confers chemoresistance in vivo, uncovering a role for miR-218 repression among its previously established protumorigeneic properties. We have identified multiple components of a receptor tyrosine kinase (RTK) signaling pathway as direct miR-218 targets and demonstrate that constitutive RTK activity reverses miR-218-mediated chemosensitivity in vivo. Moreover, we showed that HIFs, specifically HIF2α, function as downstream effectors of a low miR-218-activated RTK cascade in glioblastoma "stem-like" cells (GSCs). In strong support of our experimental findings, we observed a significant correlation between elevated HIF activity and low miR-218 expression in samples from patients with mesenchymal GBM; in contrast, no correlation was observed in proneural tumors. Collectively, our results identified an miR-218-RTK-HIF2α signaling axis that exists in highly necrotic, chemoresistant (mesenchymal) GBM. Finally, in mesenchymal GBM there is a functional association between miR-218 expression and HIF activity, with RTK activation serving as the mechanistic link between the two.
Significance
Despite measurable advances in cancer treatment, patients with glioblastoma multiforme (GBM) typically survive only 12-14 mo because of tumor recurrence. Tumor hypoxia has been associated with chemoresistance. We hypothesized that the pronounced repression of microRNA-218 (miR-218) observed in samples from patients with highly hypoxic and necrotic GBM contributes to this recurrent phenotype. We demonstrate here that mice harboring intracranial tumors with increased miR-218 expression exhibit significantly reduced tumor burden and increased survival when challenged with the chemotherapeutic agent temozolomide. Moreover, low miR-218 levels increase the expression of multiple components of the receptor tyrosine kinase signaling pathway, which promote the activation of hypoxia-inducible factor. The identification of the molecular bases for miR-218-mediated chemoresistance should promote the development of targeted therapies.
Results and Discussion
Tumors with high proliferation rates experience varying degrees of O 2 and nutrient availability, and conditions of extreme tumor ischemia can lead to necrosis. To identify important miRNAs associated with GBM ischemia, we compared two datasets of miRNA expression derived from The Cancer Genome Atlas Network (TCGA) database (Table S1 ): (i) miRNAs differentially expressed in samples from patients with GBM showing high or low levels of necrosis, and (ii) miRNAs significantly altered in GBM as compared with normal brain tissue. Among miRNAs shared by these groups, miR-218 levels were significantly decreased in highly necrotic samples (Fig. 1A and Table S1 ). Highly necrotic patient samples with low miR-218 expression also exhibited increased levels of miR-210, a previously characterized hypoxia-induced miRNA (11), validating the association between necrosis and hypoxia (Fig. 1A) . Because miR-218 expression is decreased substantially in GBM (9, 10) compared with normal brain tissue ( Fig. 1 B and C) , and miR-218 levels are further repressed in patients with highly necrotic GBM, we investigated whether hypoxia modulates miR-218 expression. Exposure to low O 2 levels inhibited miR-218 levels modestly in most human GBM cell lines (Fig. S1) ; however, miR-218 expression already is repressed significantly in these cells. Of note, miR-218 is encoded within intronic sequences of SLIT2 and SLIT3 (12, 13), and these host genes are epigenetically silenced in various cancers, including GBM (14, 15).
Mesenchymal GBM subtypes exhibit extensive necrosis, whereas overexpression of a mesenchymal gene signature is correlated with poor prognosis in patients who have GBM (6). We therefore determined whether miR-218 levels are repressed preferentially in the mesenchymal subtype. First, we used gene-expression signatures from two classifications methods (5, 6) to stratify TCGA GBM data. Consistent with previously published studies, the gene signature of Verhaak et al. (6) stratified TCGA GBM samples (n = 385) into four subtypes (mesenchymal, proneural, neural, and classical), whereas the gene signature of Phillips et al. (5) classified these tumors into three subtypes (mesenchymal, proneural, and proliferative). We compared mesenchymal and proneural subtypes because these are the only common subgroups in the classification methods of Verhaak et al. and Phillips et al. Moreover, genomic analyses by other research groups have revealed the existence of two to four major hierarchical groupings of GBM (16, 17). Huse et al. (18) reviewed the different classification methods and suggest that the proneural and mesenchymal distinction is a common theme that emerges across different clustering approaches. Moreover, gene-expression patterns in these subtypes are mutually exclusive. Hierarchical clustering using an HIF signature indicated that mesenchymal GBM exhibit higher expression levels of HIF-regulated genes than do proneural tumors, as is consistent with increased hypoxia in mesenchymal GBM (Fig. S2 ). Our analysis using either classification method also revealed significant miR-218 repression specifically in mesenchymal relative to proneural GBM, (Fig. 1 D  and E) , demonstrating that low miR-218 expression is a characteristic feature of the highly necrotic and hypoxic mesenchymal GBM subset.
Mesenchymal GBM initially respond to treatment but often recur rapidly, producing highly chemoresistant tumors with very poor prognosis (6) , and recurrent GBM from other subtypes shift toward a mesenchymal phenotype (5, 19) . Although recent studies indicate that increased miR-218 expression impacts cell viability in nasopharyngeal cancer and GBM cells (20, 21), a role for miR-218 in conferring chemoresistance was not known. To test whether miR-218 has such a role, we used a gain-of-function approach by restoring miR-218 expression in GSCs or GBM cell lines. T3691 GSCs (22) stably expressing miR-218 at levels typical of normal brain tissue (∼50 times higher than in GBM) (Fig. S3) were implanted intracranially into immunocompromised (Nu/Nu) mice. Interestingly, mice with orthotopic brain tumors derived from either T3691-SCR or T3691-218 cells revealed comparable tumor growth 12 d after transplantation (Fig. S4A) . To test whether miR-218 restoration sensitizes tumor cells to chemotherapeutic stress, we challenged transplanted animals at day 12 with temozolomide (TMZ), a widely used GBM chemotherapeutic agent ( Fig. 2A) . TMZ treatment resulted in significantly reduced growth in the miR-218-expressing (Tum-3691-218-TMZ) tumors, relative to Tum-3691-SCR-TMZ controls (Fig. 2B) . Parallel studies performed with U87-SCR and U87-218 GBM cells displayed similar results ( Fig. 2 C and D) , indicating that miR-218 expression increased the sensitivity of GSCs and GBM cells to TMZ treatment in vivo, resulting in tumor shrinkage.
To elucidate the basis of significant differences in tumor size upon miR-218 re-expression, we first analyzed cell proliferation and death in GSC tumor xenografts from mice treated with TMZ. Based on cleaved caspase 3, Ki67, and phospho-Histone 3 immunostaining, we did not observe any striking differences in apoptotic cell death (Fig. S4B ) or cell proliferation ( Fig. S4 C and D) between control and miR-218-expressing GSC tumors in mice treated with TMZ. Similarly, Ki67 staining and TUNEL analysis also demonstrated that neither cell proliferation (Fig.  S4E ) nor apoptotic cell death (Fig. S4F ) was altered between control and miR-218-expressing U87MG tumors in mice after TMZ treatment. Because of the decreased size of miR-218-expressing orthotopic lesions, we investigated the role of nonapoptotic cell death downstream of TMZ treatment. Loss of nuclear high-mobility group protein B1 (HMBG1) stain is a marker for autophagic, tumor cytolytic, or necrotic cell death (23-26), and we observed a significant reduction in nuclear HMGB1 staining in miR-218-expressing, TMZ-treated tumors in both orthotopic models (Fig. 2 E and F) . Consistent with the in vivo tumor data, miR-218-expressing T3691 GSCs or U87MG cells treated with TMZ displayed similar results in vitro ( For all statistical analyses, *P < 0.05, **P < 0.005, ***P < 0.0005. Data are presented as mean ± SEM.
identify increased nonapoptotic cell death as a mechanism to explain the reduced tumor growth in miR-218-expressing tumors treated with TMZ. A cohort of mice with orthotopic U87-SCR and U87-218 tumors was treated with DMSO or TMZ and monitored until they exhibited evidence of neurological deficits, at which time they were killed. Animals in the control U87-218-DMSO group had a modest change in median survival (22 d vs. 19 d in U87-SCR-DMSO mice) (Fig. 2G) . However, mice bearing U87-SCR intracranial tumors lived an average of 45 d after TMZ treatment, and animals receiving both miR-218 and TMZ exhibited a dramatic increase in survival: 50% failed to display any neurologic signs over 288 d (Fig. 2G) . Remarkably, brain sections from these animals lacked any detectable tumor lesions (Fig. S4I) . Of note, most of the established GBM cell lines exhibit a mesenchymal gene signature (6) . We next examined whether miR-218 levels correlate with prognosis in human GBM patients and observed that poor survival and rapid recurrence correlated with low miR-218 expression specifically in patients with mesenchymal (but not proneural) GBM treated with radiation and chemotherapy ( Fig. 2H and Fig. S5 A-C) . Furthermore, the association between poor survival of patients with mesenchymal GBM and low miR-218 expression was observed using either of the classification methods described above ( Fig. 2H and Fig. S5 A-C) (5, 6) . It is important to emphasize that mesenchymal GBM tumors are the most aggressive tumor type (6) , and observing any survival differences within this group usually is challenging because of the rapid tumor recurrence.
Although we observed enhanced chemosensitivity with high miR-218 expression (Fig. 2 B, D (29) . Therefore, establishing a role for miR-218 in chemoresistance across the two GBM groups requires an extensive study using numerous, independently derived GSCs (from both subtypes); such study is warranted in the future.
To determine why miR-218 expression is particularly repressed in mesenchymal GBM, we performed an inverse-correlation analysis between miR-218 and putative miR-218 targets identified in TCGA GBM gene-expression data using the bioinformatic program miRWalk. Among the top candidates identified in this analysis was a cluster of RTK signaling pathway members, including EGF receptor (EGFR), phospholipase C-γ1 (PLCγ1), phorphorhositide-B-IDnase, class 2, tar-polypeptide (PIK3C2A), and v-raf murine sarcoma 3611 viral oncogene homolog (ARAF), which we confirmed to be bona fide miR-218-regulated genes by mutating the miR-218 seed sequence in their corresponding 3′ UTRs and testing their activity in standard luciferase reporter assays. In each case, miR-218 expression reduced luciferase activity in a miR-218 seed sequence-dependent manner ( Fig. S6A and Table S2 ). Gene set enrichment analysis (GSEA) revealed a significant inverse correlation between the expression of EGFR, PLCγ1, or ARAF and miR-218 in samples from patients with GBM (Fig. 3A) . Furthermore, elevating miR-218 expression in GBM cell lines by stable (Fig. 3B) or transient (Fig.  S6B ) transfection reduced the abundance of EGFR, PLCγ1, PIK3C2A, and ARAF proteins. Similarly, EGFR, PLCγ1, PIK3C2A, and ARAF transcript levels were decreased in GSC T3691-218 For all statistical analyses, *P < 0.05, * P < 0.005, ***P < 0.0005. Data are presented as mean ± SEM.
orthotopic tumors with or without TMZ treatment ( Fig. S6 C and D). Analysis of reverse-phase protein array (RPPA; TCGA) for phospho-proteomic data demonstrated that p-EGFR was the target that had the greatest inverse correlation with miR-218 expression in samples from patients with GBM, supporting our hypotheses (Fig.  3C ). Of note, low miR-218 or high EGFR expression did not correlate with the downstream effectors of EGFR, indicating the complex role of RTK signaling in GBM. We also examined the effects of miR-218 on RTK pathway activity in U87-SCR and U87-218 cells exposed to various stress conditions. Ischemic stress (serumfree medium + 0.5% O 2 ) combined with TMZ treatment reduced v-akt murine thymoma viral oncogene homolog 1 (AKT) and PRAS40 phosphorylation in miR-218-expressing cells, indicating that RTK signaling is inhibited upon miR-218 introduction (Fig. S6E ). Additionally, the levels of EGFR, PLCγ1, PIK3C2A, and ARAF expression were increased in GBM compared with normal brain tissue, as revealed by a combination of transcript analyses (Fig. S7A ), examination of TCGA datasets (Fig. S7B) , and immunohistochemical (IHC) staining of a GBM tissue array (n = 40) (Fig. S7C) . Because miR-218 levels are more repressed in mesenchymal than in proneural GBM, we next determined whether the average expression of putative miR-218 targets (designated the "miR-218 target metagene") differs in these GBM subtypes. Both classification methods (5, 6) revealed a significant increase in the miR-218 target metagene in mesenchymal relative to proneural GBM subtypes (Fig. 3D ). Of note, NF1 loss is a characteristic feature of mesenchymal GBM, consistent with high levels of RTK pathway activation (6) , suggesting that low miR-218 expression potentially contributes to a hyperactive RTK state.
The importance of EGFR is well established in GBM, but the specific roles of PLCγ1, PIK3C2A, and ARAF in these cells are not completely clear. EGF stimulation promotes PLCγ1 activation through its binding to the autophosphorylated EGFR Tyr992 residue in CHO cells (30), whereas PIK3C2A is a class II PI3K isoform acting upstream of mTOR overexpressed in oral EGFR pY1173 EGFR pY1068 ) in Tum-3691-SCR and Tum-3691-218 tumors. All expression studies depicted here were performed in triplicate. For all statistical analyses, *P < 0.05, **P < 0.005, ***P < 0.0005. Data are presented as mean ± SEM.
squamous cell carcinoma (31, 32). ARAF, a member of the RAF kinase family, binds to v-raf murine sarcoma viral oncogene homolog B [BRAF (similar to CRAF)] and serves as a BRAF effector (33). Therefore, we investigated whether these direct targets contribute to miR-218-dependent chemosensitivity in vivo (Fig. 2D) . If cumulative RTK activation is required to reverse the miR-218-mediated effects on tumor growth in vivo, reintroduction of individual miR-218 targets may not be successful. Therefore, we used a plasmid encoding EGFRvIII to activate RTK signaling constitutively in miR-218-expressing cells, and a "dead kinase" (DK) construct as the control (Fig. 3E ). U87-SCR or U87-218 cells transduced with lentiviruses expressing EGFRvIII or DK proteins were implanted intracranially into immunocompromised nude mice. Interestingly, the addition of EGFRvIII completely reversed the tumor shrinkage observed upon miR-218 and TMZ treatment (Fig. 3 F and G) , confirming the role of RTK signaling in the miR-218-mediated chemosensitivity of U87 tumors. These studies indicate that miR-218 repression results in enhanced RTK activity in GBM, contributing to tumor cell survival under challenging microenvironmental conditions, including chemotherapeutic stress and severe hypoxia.
Tumor hypoxia has been linked to chemoresistance, and recent studies demonstrate that low O 2 concentrations maintain tumor stem cells in an undifferentiated state (34, 35). HIFs (and HIF2α in particular) promote GSC self-renewal, proliferation, and survival (36). Furthermore, high HIF2α levels correlate with poor survival in patients with glioma (36). Previous reports demonstrated that multiple components of RTK signaling promote HIF expression, with consequent effects on tumor angiogenesis and response to therapy (37-39). GSEA revealed that low miR-218 abundance is significantly associated with an enrichment of HIF signature genes in human GBM samples (Fig.  4A) , as is consistent with our hypothesis that low miR-218 promotes HIF activation through RTK signaling. To test this premise, we stably expressed miR-218 in T3691 and T4302 GSCs and observed reduced transcription of HIF2α-regulated genes (e.g., TGF-α, VEGF, and GLUT1); in contrast, HIF1α-regulated genes (PGK1, PDK1, and ALDOA) were not inhibited by miR-218 treatment ( Fig. 4B and Fig. S8A) . Consistently, the introduction of miR-218 inhibited HIF2α,but not HIF1α mRNA levels in T3691 (Fig. 4C ) and T4302 GSCs (Fig. S8B ). To test whether this effect was dependent on RTK activation in cells with low miR-218 expression, we used RTK inhibitors and analyzed the accumulation of HIFα isoforms and their downstream target genes. Although the abundance of both HIFα transcripts was reduced by RTK inhibition, HIF2α levels again were significantly lower than those of HIF1α (Fig. 4D) . Moreover, HIF2α-regulated target genes (SERPINE1 and TGF-α) were preferentially repressed by RTK inhibition (Fig. S8 C and D) , revealing a mechanism whereby low miR-218 expression promotes tumor cell survival in GBM.
To determine how HIF2α is transcriptionally regulated by RTKs in GBM, we analyzed its promoter region for transcription factors controlled by RTK signaling pathways and identified jun protooncogene (c-JUN) as a potential candidate (ENCODE; http:// genome.ucsc.edu/cgi-bin/hgGateway). Interestingly, siRNAmediated suppression of c-JUN inhibited HIF2α but not HIF1α expression in T3691 and T4302 GSCs (Fig. 4E and Fig. S8 E and  F) . Because c-JUN is activated mainly through JNK signaling (40), we assessed the impact of JNK inhibition on HIFα expression and observed reduced HIF2α but not HIF1α mRNA levels in T3691 and T4302 GSCs (Fig. 4F and Fig. S8 G and H) . Because HIF2α expression is transcriptionally enhanced in hypoxic GSCs (36), we next investigated whether HIF2α stimulation is JNK dependent and determined that JNK inhibition significantly attenuated hypoxic induction of HIF2α but not of HIF1α ( Fig. 4G and Fig. S8I ). Therefore, a molecular link between miR-218-mediated RTK activation and HIF2α expression involves JNK signaling via c-JUN. It is important to note that HIF2α was not predicted to be a direct miR-218 target by multiple bioinformatics analyses, indicating that miR-218 regulation of HIF2α is indirect, presumably through RTK signaling pathways.
Because hypoxia promotes tumor angiogenesis (41), a characteristic feature of highly aggressive mesenchymal GBM, we characterized vessel density and pericyte coverage in tumor blood vessels. Although no difference in vascular area (based on CD31 recently demonstrated that GSCs can transdifferentiate into pericytes, and delineating a role for an miR-218-RTK-HIF2α signaling axis in this process is warranted in the future. Taken together, our studies indicate that low miR-218 expression promotes RTK and HIF activation in mesenchymal GBM, contributing to chemoresistance and tumor vascularization.
Finally, because miR-218 levels were further reduced in mesenchymal relative to proneural GBM, we analyzed the functional significance of an miR-218-RTK-HIF signaling axis in these GBM subtypes. Samples from patients with mesenchymal or proneural GBM were divided into two groups ("high" and "low") based on miR-218 expression. Interestingly, samples from patients with mesenchymal GBM with low miR-218 levels exhibited elevated expression of an HIF metagene (Fig. 5A ), supporting our contention that low miR-218 increases HIF activation. Similarly, GSEA revealed an inverse correlation between an HIF gene signature and miR-218 expression in mesenchymal GBM (Fig. S9A) . Importantly, no significant association was observed between miR-218 levels and the HIF metagene (Fig. 5B) or the HIF gene signature (Fig. S9B ) in proneural GBM. We concluded that the miR-218-RTK-HIF2α signaling pathway operates preferentially in highly aggressive mesenchymal GBM.
Although the use of miRNAs for therapeutic intervention is still in its earliest phases of development, our study suggests that the combined use of synthetic miR-218 with chemotherapeutic agents could be beneficial for patients who have GBM, particularly those with mesenchymal tumors. Most importantly, we demonstrate that miR-218 functions as a tumor suppressor in GBM by targeting multiple components of RTK signaling pathways ( Fig. 5C ) and reveal mechanisms whereby low miR-218 expression promotes GBM tumorigenesis.
Materials and Methods
We obtained formalin-fixed paraffin-embedded tissues from 30 GBM cases (World Health Organization grade IV/IV) and 12 controls from the Department of Pathology and Laboratory Medicine, University of Pennsylvania. GBM blocks contained more than 95% tumor cells. Controls consisted of temporal lobectomy specimens obtained from patients with intractable epilepsy and showed histopathologic evidence of mild to focally moderate gliosis but no lesions. GBM
Other information on materials and methods is described in SI Materials and Methods.
ACKNOWLEDGMENTS. We thank Hongwei Yu for histological preparations, Paul Hallberg for assistance with cell sorting, and the members of the M.C.S. laboratory for helpful discussions and comments. This work was funded by the Howard Hughes Medical Institute and National Institutes of Health Grant CA104838. M.C.S. is an investigator of the Howard Hughes Medical Institute. In Vivo Xenograft Tumor Assays. All experiments in mice were approved by the University of Pennsylvania Institutional Animal Care and Use Committee and were performed in accordance with National Institutes of Health guidelines. Intracranial xenograft tumor assays were performed in Nu/Nu mice, as described (2). Briefly, GSC T3691 tumor spheres (50,000 cells; T3691-SCR or T3691-218) in a total volume of 5 μL were implanted into the right frontal lobes of nude mice. The animals were killed on day 25 after implantation. Similarly, 500,000 U87-SCR or U87-218 cells were used for the parallel intracranial study to analyze the effect of increased microRNA-218 (miR-218) expression on survival. Mice were screened for neurological symptoms and killed upon exhibition of detectable signs. For the rescue experiments, EGFRvIII was re-expressed in U87-SCR or U87-218 cells, and intracranial experiments were performed as described above. MedCalc software was used to produce a Kaplan-Meier survival curve. Measurements of tumor area were calculated using Image J software.
Statistics. Statistical analyses to evaluate the differences between the control and experimental groups were assessed using an unpaired two-tailed Student's t test for most of the studies, unless specified. Quantified data shown represent at least three independent experiments. MedCalc software was used to conduct all statistical analyses. Luciferase Reporter Assay. The 3′ UTR of phospholipase C-γ1 (PLCγ1), EGFR, phorphorhositide-B-IDnase, class 2, tar-polypeptide (P1K3C2A), and v-raf murine sarcoma 3611 viral oncogene homolog (ARAF) were cloned into the pMIR-REPORT microRNA (miRNA) expression reporter vector (ABI). Fortyeight hours after stable miR-218 expression in T98G cells, the respective plasmids were transfected into cells with the Fugene 6 transfection reagent (Roche) in 24-well plates. A plasmid expressing Renilla Luciferase was cotransfected and used to normalize the firefly Luciferase values expressed from the pMIR-REPORT expression vector. Luciferase assays were performed using the dual luciferase protocol (Promega) 48 h after transfection of the corresponding plasmids containing the 3′ UTR regions. To test the role of specific seed sequences in the 3′ UTR of miR-218 target genes, mutations were introduced into the miR-218-binding seed sequences and were compared with the wild-type sequence. The duplex sequences were cloned into pMIR-REPORT expression vector for further luciferase analysis (Table S2) .
Quantitative Real-Time PCR. Total RNA was isolated using the miRNeasy mini kit (Qiagen) and was reverse transcribed into cDNA using the High Capacity RNA-to-cDNA kit (ABI). To analyze miR-218 expression, the TaqMan MicroRNA Reverse Transcription Kit (ABI) was used according to the manufacturer's instructions. Taqman primers were used to measure transcript levels, and analyses were performed on the ABI 7900HT system (ABI) ( Table S2 ). All target mRNA levels were normalized to 18s expression levels. Sequences for the 18s SYBR Green primer set are GAATTCCCAGTAAGTGCGGG forward and GGGCAGGGACTTAATCAACG reverse. The quantitative RT-PCR (qRT-PCR) data reflect average mRNA levels from three independent RNA extractions and reverse transcription reactions with error bars showing SEM. miR-218 target expression in orthotopic xenograft tumors was analyzed using RNA isolated from 10-μM paraffin sections using the Recover All Total Nucleic Acid Isolation Kit (Ambion).
Western Blot, Immunohistochemistry, and Immunofluorescence.
According to the experimental time points, cells were lysed by standard procedures in lysis buffer containing a protease inhibitor mixture. Protein lysates (40 μg) were resolved on SDS/PAGE gels followed by immunoblot detection and visualization with the ECL kit (PerkinElmer). Antibodies and concentrations used for immunoblots were rabbit PIK3C2A (1:100; Abgent) and rabbit PLCγ1, rabbit β-tubulin, rabbit EGFR, and rabbit ARAF (all at 1:1,000 dilution; Cell Signaling). For immunohistochemistry (IHC) and immunofluorescence (IF) analysis, mice were killed and were whole-body perfused by PBS and 4% (wt/vol) paraformaldehyde (PFA), followed by fixing in 4% (wt/vol) PFA for 24 h at 4°C. Mouse brain sections with xenograft tumors were dehydrated through an inclining EtOH series into 100% (vol/vol) EtOH, treated with Xylene, and embedded in paraffin (n = 3-5). H&E staining was performed by standard protocols. IHC and IF were performed on 5-μm sections based on standard procedures.
Antibodies and the concentrations used for IHC and IF were rabbit PLCγ1 (1:100; Novus Biologicals), rabbit Ki67 (1:100; BD Biosciences), smooth muscle actin (SMA) (1:250; Sigma), rabbit CD31 (1:50; Abcam), cleaved caspase 3 (1:50; Cell Signaling), and rabbit high-mobility group protein B1 (HMGB1) (1:100; Abcam). Brain glioblastoma and normal tissue array (40 cases; 80 cores) was purchased from Biomax (GL806). The paraffin-embedded tissue array processing for IHC analysis was performed as described earlier. IF analysis was performed on cells grown on coverslips by fixing the cells with 4% (wt/vol) PFA for 10 min, followed by permeabilizing with 0.1% Triton-X for 10 min. Primary rabbit HMGB1 (1:100; Abcam) and secondary antibody incubations were performed according to standard protocols. Image analyses and quantifications were performed using a Leica 500 microscope (Leica) as well as Image J.
The Cancer Genome Atlas Microarray Data Analysis. Available data for gene expression, miRNA expression, methylation, and copy number were downloaded from the Cancer Genome Atlas (TCGA) data portal. All microarray data were analyzed using Partek software (Partek Inc.). For gene expression, data generated on Affymetrix microarray platform HT_HG-U133A for 385 tumor and 10 normal samples were subjected to GC robust multiarray average (GCRMA) normalization (GCRMA background correction, quantile normalization, log2 transformation, and Median polish probeset summarization). In the case of miRNA expression, previously normalized TCGA level 2 data from 426 tumor samples and 10 normal samples run on Agilent's miRNA microarray were used. Sample classification into different subtypes. Samples were classified into proneural, neural, classical, and mesenchymal subtypes based on a robust 840-gene expression signature developed and described by Neil Hayes and his group (3). Training and prediction were carried out using an R implementation of ClaNC software, a nearest centroid-based classifier (4). A training set comprising 173 samples and 840 genes was used to predict classes in 385 TCGA gene-expression samples exactly as described by Hayes et al. The resulting proportions of classes were similar to those in the training and to the validation set of 260 samples that the authors used in their study. Similarly, the clustering classification of Phillips et al. (5) was performed using the published gene signature. Survival analysis. All available patient survival data including treatment response were integrated with miR-218 expression. The predicted GBM subtypes were integrated also. KaplanMeier survival analysis was carried out to determine an association between survival and miR-218 expression in all GBM types or in different GBM subtypes. An association was considered significant if the P value of association analysis was <0.05. Correlation analysis for identification of miR-218 targets. For TCGA gene expressions, we chose the probe with the maximum variation. For miRNA, level 2 Agilent data were downloaded and used for the analysis. From the TCGA database, a standardized gene and miRNA set consisting of GBM patients was collated. The patients were ranked according to miR-218 expression levels.
Whole-genome analysis by Comparative Marker Selection (CMS, gene pattern suite, Broad Institute, MIT) revealed the top-downregulated and inversely correlated genes in patients with high miR-218 expression. Then this list was compared with predicted miR-218 gene targets using miRWalk. Genes were ranked according to both the predictive power of miR-218 binding and average P value across the four discovery sets (6) . For visualization, a geneexpression heatmap was created using dChip software (http://www. biostat.harvard.edu/~cli/dchip_2010_01.exe).
Correlation of necrosis with miRNA expression. TCGA Glioblastoma level 1 expression data were obtained for mRNA expression (http://cancergenome.nih.gov/). Robust multiarray analysis was performed in R (R Project, www.r-project.org/). Histopathology annotation for the percent of necrosis was downloaded from the public TCGA data portal. The percent of necrosis was averaged across the available sections for each patient and matched to the corresponding TCGA dataset. Then the percent of necrosis was plotted against the miRNA expression. Significance was calculated using Student's t test and ANOVA with SAS JMP Pro-10 software (SAS Institute Inc.).
Correlating miR-218 expression with the hypoxia-inducible factor signature and miR-218 target genes. To determine the association between miR-218 and expression of the hypoxia-inducible factor (HIF) signature, we used the Gene Set Analysis (GSA) implementation (version 1.03) of Gene Set Enrichment Analysis (GSEA). The HIF signature was defined by using established HIF-regulated genes (7). For GSA, the expression value of miR-218 was used as a quantitative response variable and compared with gene sets comprised of the HIF signature and sets of random genes of equal size. Restandardization using the entire expression data was performed, and the maxmean statistic was used. The significance for the HIF signature enrichment was calculated based on 1,000 permutations. To determine the association between miR-218 expression and our list of miR-218 target genes, GSA was repeated using a gene set of the four newly identified miR-218 targets.
To create a single value that represents the expression of the HIF signature (HIF metagene), the average expression of all the genes in the HIF signature was calculated for each tumor sample (using TCGA GBM data). This HIF metagene then was used as a continuous variable for various comparisons between groups. Similarly, an miR-218 target metagene was generated using the average expression of PLCγ1, EGFR, P1K3C2A, and ARAF for each tumor sample (TCGA data). All analysis was performed using the R language and environment for statistical computing.
Correlation of reverse phase protein array data with miR-218 expression.
Reverse phase protein array (RPPA) data were downloaded from the TCGA (http://app1.bioinformatics.mdanderson.org/tcpa/_design/ basic/index.html). Phospho-proteins that are significantly associated with miR-218 expression were determined by Significance Analysis of Microarray using a median false-discovery rate of 0.05. Only TCGA GBM samples for which RPPA data are available were used for the analysis. HMOX1  ADM  NDRG1  BNIP3L  IGFBP3  LDHA  PGK1  EGLN3  CA12  TFR2  TFRC  LOX  CP  EGLN1  BNIP3  CA9  PFKFB3  CDKN1A  SERPINE1  PFKFB4  FLT1  HK1  EDN1  TGFA  TGFB3 IGFBP3  TGFB3  EGLN1  CP  PFKFB4  CA12  BNIP3L  CA9  TFRC  HMOX1  EDN1  CDKN1A  ADM  LDHA  SERPINE1  PGK1  EDN2  FLT1  TFR2  PFKFB3  BNIP3  EGLN3  LOX  NDRG1  TGFA 
